Peptides studied for blood-vessel growth and mitochondrial capacity relevant to heart health and endurance
Cardiovascular capacity depends on two things: blood vessels that carry oxygen to working tissue, and the mitochondria inside cells that use that oxygen to make energy. The compounds here split along those lines — LL-37 and TB-500 are studied for new blood-vessel growth, while humanin, MOTS-c, SS-31 and epithalon are studied for mitochondrial function. Most of this evidence comes from laboratory and animal work; only SS-31 has advanced substantially into human cardiovascular trials.
1The biology of this goal
Your heart and muscles need a steady supply of oxygen to keep working during effort. Oxygen travels through blood vessels, so growing new vessels and keeping existing ones open helps tissue get what it needs. Once oxygen arrives, tiny structures inside cells called mitochondria burn fuel with it to make energy. If mitochondria work well, cells produce more energy and create less internal damage; if they falter, endurance and heart function suffer. The peptides in this brief are studied either for helping build new blood vessels or for protecting and improving how mitochondria work.
A human-focused review reports LL-37 stimulates angiogenesis and tissue regeneration, while its specific cardiovascular protective role rests on weaker community and practitioner-level sources.
LL-37 is the only human cathelicidin, a small peptide made by immune cells and skin that is best known for killing microbes. Beyond that, sources report it also helps build new blood vessels and supports tissue repair, which is why it appears here for the blood-vessel side of cardiovascular capacity.
LL-37 stimulates angiogenesis (new blood-vessel growth), tissue regeneration, and cytokine release such as IL-8.1
Sources describe LL-37 having cardiovascular protection and stimulating angiogenesis through VEGF signalling.2
Cathelicidins including LL-37 are reported to play a role in angiogenesis, wound healing, and the regulation of programmed cell death.3
What this doesn't establish
None of the supplied evidence tests LL-37 for endurance, cardiac output, or blood-vessel growth in a human cardiovascular setting; the angiogenesis claims come from immune-defense and wound-healing contexts, not heart or exercise studies.
Animal and laboratory studies suggest thymosin beta-4 supports angiogenesis and improves cardiac cell survival and function after injury.
TB-500 is a lab-made version of thymosin beta-4, a peptide found naturally in nearly every human cell. Its main job is organising actin, the protein that lets cells move to injury sites and rebuild tissue. In animal studies it is reported to promote new blood vessels and to help the heart survive and function better after injury.
Thymosin beta-4 is expressed in the developing heart, promotes cardiac cell migration and survival, and improves cardiac function after coronary artery ligation in adult animals.5
TB4 is involved in angiogenesis, cell survival, cell migration and fetal development; maternal treatment advanced heart, lung and kidney development in mice.4
Sources report TB-500 promotes endothelial cell migration and angiogenesis, reduces inflammation, and note a potential effect on blood pressure worth monitoring in hypertensive individuals.6
What this doesn't establish
The cardiac benefits were seen with full-length thymosin beta-4 in animals, not with the injected fragment vendors sell, and no human trial here demonstrates improved heart function or endurance; one practitioner source also flags a possible effect on blood pressure.
A human-focused review places humanin within age-related mitochondrial and cardiovascular biology, while its cell-protective effects rest on in vitro and animal disease models.
Humanin is a small peptide encoded inside the mitochondria — the cell's power plants — and it acts as a stress signal the mitochondria send out to protect cells. Its levels fall with age. In cell and animal studies it is reported to protect heart and other cells from damage and death, which is relevant to keeping mitochondria and tissue viable.
Alterations of humanin levels are associated with aging and could influence age-related metabolic, cardiovascular and neurological disease; a compensatory rise could preserve mitochondrial function and cellular vitality.7
Excessive humanin concentrations can have harmful consequences and are associated with cancer and heart failure.7
In vitro and in vivo studies report humanin protects cells and suppresses apoptosis in cardiovascular, diabetic, and neurodegenerative disease models.8
Humanin has shown beneficial effects in diverse disease models including stroke and cardiovascular disease.9
What this doesn't establish
No human trial of administering humanin as a drug has been published, and the sources note that both too little and too much humanin can be harmful — so a beneficial dose or effect on heart health or endurance in people is not established.
A tier-1 source establishes MOTS-c as a cytoprotective mitochondrial-derived peptide, while its exercise-mimetic and cardiac-protective effects come from animal and laboratory studies.
MOTS-c is a small peptide encoded in mitochondrial DNA that behaves like an exercise signal. It switches on AMPK, a cellular energy sensor that tells cells to burn fuel more efficiently and handle sugar better. Because exercise raises MOTS-c and the peptide reproduces several exercise-like effects in animals, it is often called an 'exercise-mimetic' — directly relevant to endurance and mitochondrial capacity.
MOTS-c is a mitochondrial-derived peptide encoded by mitochondrial DNA that preserves mitochondrial function and cell viability under stress.11
MOTS-c is expressed across tissues including heart; injection in mice reduced blood glucose and visceral fat with results similar to aerobic exercise.10
MOTS-c activates the Keap1-Nrf2 antioxidant pathway and, with exercise, modulated antioxidant defenses to reduce diabetic myocardial damage in rat heart tissue.10
MOTS-c is proposed for application in aging, cardiovascular disease, insulin resistance and inflammation.12
What this doesn't establish
The exercise-mimetic and heart-protective findings are from rodent diabetes and fibrosis models, not human endurance or cardiac trials, so a benefit to human cardiovascular capacity is not established.
Human trials have investigated elamipretide for heart failure and mitochondrial disease, and animal studies report restored cardiac mitochondrial function — the strongest cardiovascular evidence in this brief.
SS-31, also called elamipretide, is a synthetic peptide that homes directly into mitochondria and concentrates hundreds to thousands of times over inside them. It binds cardiolipin, a fat unique to mitochondria that keeps the energy-making machinery organised. By protecting cardiolipin it helps preserve mitochondrial structure, boosts energy (ATP) production, and cuts harmful reactive molecules at their source — making it the most directly targeted mitochondrial compound here.
Preclinical studies demonstrate protective and restorative efficacy of elamipretide in models of heart failure, ischemia-reperfusion injury, metabolic syndromes, and muscle weakness.13
Elamipretide increased left ventricular ejection fraction in dog models of heart failure with reduced ejection fraction and prevented left ventricular remodeling in rats.14
In a canine heart failure model, elamipretide restored Complex I and Complex IV enzymatic activity and normalised the ATP/ADP ratio from 0.38 to 1.16.15
SS-31 has been investigated in clinical trials for heart failure with reduced ejection fraction, primary mitochondrial myopathy, dry AMD, and renal ischemia-reperfusion injury.15
What this doesn't establish
The tier-1 cardiac efficacy data are from dog and rat models, and while it has entered human cardiovascular trials the supplied sources do not establish a proven endurance or heart-function benefit in healthy people; its FDA approval is specific to Barth syndrome.
Animal and laboratory studies show epithalon alters heart gene expression, and limited, independently unconfirmed Russian human data suggest effects on cardiovascular mortality in the elderly.
Epithalon is a synthetic four-amino-acid peptide modeled on an extract from the pineal gland. It is mainly studied for aging — turning on the telomerase enzyme, restoring nighttime melatonin, and acting as an antioxidant. Its link to heart health is indirect: it changes gene activity in heart tissue and some Russian studies report reduced cardiovascular mortality in older people.
Epithalon modulated expression of 98 of 15,247 cDNA clones in mouse heart, showing specific effects on cardiac gene expression.16
Limited human clinical data from Russian studies suggest effects on melatonin rhythms, retinal function, and cardiovascular mortality in elderly populations.17
Several Russian clinical trials suggest the related extract epithalamin may decrease mortality in older adults with cardiovascular disease, but these results have not been independently confirmed.18
What this doesn't establish
There is no direct evidence that epithalon improves mitochondrial function, endurance, or heart performance; the human cardiovascular-mortality data are unconfirmed by independent groups and the mechanism relevant to this goal is not established.
These compounds divide cleanly into two arms of the goal. On the blood-vessel side, LL-37 and TB-500 are described as complementary: both promote angiogenesis and reduced inflammation but through distinct routes — LL-37 via VEGF and keratinocyte migration, TB-500 via actin and cell migration. On the mitochondrial side, SS-31 pairs complementarily with each of the mitokines: SS-31 physically stabilises cardiolipin at the machinery level, while MOTS-c works upstream through AMPK and Nrf2 antioxidant genes and humanin signals survival through receptors — non-overlapping mechanisms converging on better mitochondrial function. Humanin and MOTS-c are likewise described as complementary mitokines covering different arms of the same stress response. One caution: humanin and LL-37 both act on the FPR2 receptor, so combining them is more likely to be redundant than additive, and choosing one FPR2-directed agent makes more sense than stacking both. Epithalon is framed as a complementary geroprotector alongside humanin, MOTS-c and SS-31 through unrelated antioxidant and telomerase pathways. Several pairs — TB-500 with the mitochondrial peptides, and SS-31 or MOTS-c with LL-37 — have no documented interaction in our data, which is an absence of evidence rather than a clearance.
Humanin + LL-37
Worth caution — see why below
Both LL-37 and humanin act on the formyl peptide receptor FPR2 and share anti-inflammatory, cytoprotective signaling. Because they engage the same receptor, combining them is more likely to be redundant (competing for the same target) than additive, so it makes more sense to choose one FPR2-directed agent rather than stack the two.
Not fully established
The mechanism descriptions clearly establish that both LL-37 and humanin target FPR2 (formyl peptide receptor 2). LL-37 is described as targeting 'FPR2 (formyl peptide receptor 2)' and humanin targets 'Formyl peptide receptors FPR2/FPR3 (FPRL1)'. Both peptides are also documented to have anti-inflammatory effects: LL-37 shows 'Immunomodulation (both anti- and pro-inflammatory)' with anti_inflammatory tag, and humanin shows 'Anti-inflammatory / reduced pro-inflammatory cytokines (reported)' with anti_inflammatory tag. The shared dimension of anti-inflammatory activity combined with the documented shared FPR2 receptor target justifies the 'same_mechanism' relationship type and the reasoning that they may compete for the same receptor, making them potentially redundant rather than additive.
Humanin + SS-31
May be complementary
Both aim to protect mitochondria and reduce oxidative/ischemic injury, but by different means: SS-31 physically stabilizes the inner-membrane cardiolipin and electron-transport supercomplexes to preserve ATP output and cut ROS, whereas humanin signals through receptors to trigger anti-apoptotic and anti-inflammatory programs. One protects mitochondrial machinery directly, the other signals survival — a genuinely complementary combination.
Not fully established
Both peptides' mechanisms clearly support the complementary relationship with the claimed shared dimensions. The mechanism material explicitly establishes: (1) Both target mitochondrial_function—SS-31 directly stabilizes cardiolipin, cristae, and ETC supercomplexes to preserve ATP and reduce ROS; humanin enhances mitochondrial biogenesis and bioenergetics. (2) Both target anti_inflammatory—SS-31 modulates inflammation/pyroptosis; humanin reduces pro-inflammatory cytokines via JAK2/STAT3 and SIRT1. (3) The explanation accurately characterizes their distinct mechanisms: SS-31 acts through direct physical stabilization of inner-membrane structures and oxidative phosphorylation, while humanin acts through receptor signaling (FPR2/FPR3, gp130) to trigger cytoprotection and anti-apoptotic programs. These are genuinely different mechanistic approaches (direct structural vs. signaling-mediated) that converge on shared protective outcomes, meeting the definition of complementarity. The mechanisms do not contradict this relationship; they substantiate it.
Humanin + MOTS-c
May be complementary
Both humanin and MOTS-c are mitochondrial-derived peptides ('mitokines') that signal cellular stress and improve metabolism, but they work through different downstream routes — humanin is chiefly cytoprotective/anti-apoptotic (Bax inhibition, STAT3, PI3K/Akt) while MOTS-c drives AMPK activation and Nrf2 antioxidant responses. Together they cover complementary arms of the same mitochondrial-stress response, which is why they are often discussed as a metabolic/longevity pairing.
Not fully established
Both peptides' mechanisms clearly establish them as mitochondrial-derived peptides (mitokines) with distinct but complementary pathways. Humanin targets anti-apoptotic Bcl-2 family members and activates JAK2/STAT3 and PI3K/Akt, while MOTS-c activates AMPK and the Keap1-Nrf2 antioxidant axis. Both are explicitly tagged with mitochondrial_function and anti_inflammatory in their approved tags. The mechanisms support the claim of complementary action: humanin's cytoprotection via apoptosis inhibition and STAT3 signaling differs from MOTS-c's AMPK-driven metabolic remodeling and Nrf2-mediated antioxidant stress response. Both improve insulin sensitivity and glucose metabolism through different routes, and both are described as mitokines signaling cellular/mitochondrial stress. The shared dimensions (mitochondrial_function, anti_inflammatory) are directly supported by the tagged attributes and mechanism descriptions, and the explanation accurately reflects the distinct downstream pathways documented in each peptide's mechanism material.
TB-500 + LL-37
May be complementary
Both promote wound healing, new blood-vessel growth (VEGF), and reduced inflammation, but through distinct mechanisms — LL-37 drives keratinocyte migration and angiogenesis via EGFR/FPR2, while TB-500 regulates actin/cytoskeletal dynamics and cell migration. This makes them a strong complementary tissue-repair pairing.
Not fully established
Both peptides' mechanisms clearly establish the four shared dimensions claimed. LL-37 explicitly targets EGFR, FPR2, and TLR pathways leading to angiogenesis, wound healing, and keratinocyte migration with VEGF/VEGFA signaling noted. TB-500 explicitly targets integrins and G-actin for cell migration, angiogenesis via VEGF, and tissue remodeling. Both show anti-inflammatory effects (LL-37 via NF-κB/TLR signaling; TB-500 via NF-κB suppression and reduced TNF-α/IL-1β/IL-6). Both list tissue_repair, angiogenesis, anti_inflammatory, and VEGF_upregulation in approved tags. The explanation correctly identifies distinct mechanistic pathways (LL-37: EGFR/FPR2/keratinocyte-driven; TB-500: actin/cytoskeletal/integrin-driven) that would complement rather than duplicate each other. The relationship type 'complementary' is well-justified by the mechanism material.
Humanin + Epithalon
No known conflict in the research
Both are studied as geroprotective peptides that reduce oxidative stress and are reported to extend healthspan in animal models, but epithalon acts on telomerase/hTERT and circadian-melatonin gene regulation while humanin works through mitochondrial cytoprotection. Distinct anti-aging mechanisms with a shared longevity goal.
Not fully established
Both peptides' mechanisms support a complementary relationship focused on mitochondrial_function and geroprotection. Humanin is explicitly described as a 'mitokine' encoded in the mitochondrial genome that enhances mitochondrial biogenesis/bioenergetics and has approved tag 'mitochondrial_function.' Epithalon has the same approved tag 'mitochondrial_function' and includes antioxidant/mitochondrial ROS modulation in its pathways. Both are reported to extend lifespan/healthspan in animal models through distinct mechanisms—humanin via direct mitochondrial cytoprotection and anti-apoptosis, epithalon via telomerase activation and circadian-melatonin restoration. The explanation accurately characterizes these as complementary (non-overlapping but synergistic) approaches to geroprotection that both address mitochondrial function and oxidative stress, justifying the proposed relationship and shared dimension.
SS-31 + Epithalon
No known conflict in the research
SS-31 stabilizes cardiolipin and cuts mitochondrial ROS at the source, whereas Epithalon's reported benefits run through telomerase and general antioxidant/senescence pathways. Both reduce oxidative/mitochondrial aging burden via unrelated mechanisms, making them plausibly complementary.
Not fully established
Both peptides' mechanisms establish mitochondrial_function as a shared dimension through distinct pathways: SS-31 directly targets cardiolipin, mPTP, and ETC supercomplexes to reduce mitochondrial ROS production and preserve mitochondrial structure; Epithalon activates telomerase and antioxidant pathways while modulating mitochondrial ROS. The proposed relationship as 'complementary' is justified—they address mitochondrial aging burden through unrelated mechanisms (direct mitochondrial targeting vs. telomerase/antioxidant upregulation), making them mechanistically non-overlapping yet synergistic for the shared dimension of mitochondrial function. Both peptides' approved tags include 'mitochondrial_function,' confirming this shared dimension is recognized in their mechanism profiles.
SS-31 + MOTS-c
No known conflict in the research
Both aim to protect and improve mitochondria but by different routes: MOTS-c works upstream through AMPK activation and Nrf2/ARE antioxidant gene expression, while SS-31 physically stabilizes cardiolipin and the electron-transport-chain supercomplexes to reduce ROS at the source. These are non-overlapping mechanisms converging on the same goal of better mitochondrial function and lower oxidative stress, making them a plausibly synergistic pairing.
Not fully established
The mechanisms clearly establish both shared dimensions. (1) Mitochondrial_function: MOTS-c improves mitochondrial function via AMPK activation and metabolic pathway modulation (folate-methionine cycle disruption); SS-31 directly stabilizes cardiolipin, ETC supercomplexes, and ATP synthase to enhance oxidative phosphorylation and ATP synthesis. Both target mitochondrial function but through distinct routes. (2) Anti_inflammatory: MOTS-c has anti-inflammatory effects via STAT3/IL-10 regulation and Keap1-Nrf2 pathways; SS-31 modulates inflammation/pyroptosis through ferroptosis suppression and BDNF signaling. The explanation correctly identifies these as non-overlapping upstream (MOTS-c: gene expression/AMPK) versus downstream (SS-31: direct structural/bioenergetic) mechanisms converging on mitochondrial protection and ROS reduction. This is a valid complementary relationship supported by the provided mechanisms.
Epithalon + MOTS-c
No known conflict in the research
Both are longevity-oriented peptides converging on antioxidant defense and metabolic/mitochondrial health via distinct mechanisms — MOTS-c drives AMPK/PGC-1α mitochondrial biogenesis and NRF2 antioxidant response, while Epithalon works through telomerase, senescence-pathway, and circadian/antioxidant modulation. Complementary geroprotective strategies.
Humanin + TB-500
No documented interaction in our data — that is not a safety clearance.
TB-500 + SS-31
No documented interaction in our data — that is not a safety clearance.
TB-500 + Epithalon
No documented interaction in our data — that is not a safety clearance.
TB-500 + MOTS-c
No documented interaction in our data — that is not a safety clearance.
SS-31 + LL-37
No documented interaction in our data — that is not a safety clearance.
Epithalon + LL-37
No documented interaction in our data — that is not a safety clearance.
MOTS-c + LL-37
No documented interaction in our data — that is not a safety clearance.
4Compounds we looked at and left out
These share some biology with this goal, so you may have seen them recommended for it. Here is what our own research says about each.
Semax is linked to new blood-vessel growth, but in this compound that activity is about stroke recovery and cerebral blood circulation restoration.
“After brain injury such as stroke, it appears to dial down inflammation and oxidative stress while turning on genes tied to nerve repair, new blood vessels, and neuron survival.”— from its own profile
Semaglutide is linked to mitochondrial function, but in this compound that activity is about weight loss and blood glucose control.
“It also acts on appetite regulation and slows the rate at which the stomach empties, leading to reduced food intake and weight loss.”— from its own profile
Cerebrolysin is linked to mitochondrial function, but in this compound that activity is about neurological protection and brain function.
“Researchers propose it protects neurons by reducing cell death, calming inflammation, lowering oxidative stress (free radicals), and supporting blood vessels in the brain.”— from its own profile
Noopept is linked to mitochondrial function, but in this compound that activity is about cognitive enhancement and neuroprotection.
“Animal and cell studies attribute its cognitive and neuroprotective actions to raising the neurotrophic factors BDNF and NGF, boosting acetylcholine signaling, reducing oxidative stress and glutamate excitotoxicity, and increasing HIF-1 activity.”— from its own profile
5What we can't tell you yet
This library cannot yet speak to the nitric-oxide pathway, which governs blood-vessel dilation — no compound here is linked to it — so the vessel-widening side of oxygen delivery is not covered. The strongest human cardiovascular data are limited to SS-31; for the other compounds the cardiovascular and endurance claims rest on animal, laboratory, or unconfirmed human sources, and none directly measure endurance capacity in healthy people.
No compound in our library is currently linked to nitric-oxide pathway.
This brief reports what published research says about these compounds. It is information, not medical advice, and not a recommendation to use anything described here. Evidence quality varies by compound and is labelled throughout. Talk to a qualified clinician before acting on any of it.